Dr Jeremy Braybrooke
BSc, BM, FRCP, PhD
Senior Clinical Research Fellow
Jeremy is a Consultant Medical Oncologist and clinical lead for oncology at University Hospitals Bristol NHS Foundation Trust. He trained in Medical Oncology at the Cancer Research UK Medical Oncology unit in Oxford. During this time he completed a PhD in DNA damage and repair pathways. Jeremy has worked in Bristol since 2003 and developed a large research focussed clinical practice specialising in breast and testicular cancers. Jeremy sits on a NICE Technology Appraisal Committee evaluating new medicines and is a member of the Royal College of Physicians Specialist Advisory Committee for medical oncology training. He is actively involved in clinical research and since 2016 has worked part time as a Senior Clinical Research Fellow within EBCTCG.
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.
Turner NC. et al, (2020), Lancet Oncol, 21, 1296 - 1308
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials
Hudeček J. et al, (2020), npj Breast Cancer, 6
Results from plasmaMATCH: a multiple parallel cohort, multi-centre clinical trial of circulating tumour DNA testing to direct targeted therapies in patients with advanced breast cancer
Ring A. et al, (2020), BREAST CANCER RESEARCH AND TREATMENT, 180, 531 - 531
Improvements in long-term outcome for women with estrogen receptor positive (ER plus ) early stage breast cancer treated with 5 years of endocrine therapy: Analyses of 82,598 women in the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) database
Pan H. et al, (2020), CANCER RESEARCH, 80
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer.
Kos Z. et al, (2020), NPJ Breast Cancer, 6